Biogen will find out in early 2021 whether it will have the largest sales opportunity for the pharmaceuticals industry in at least a decade. Meanwhile, the drug company’s stock is a worthy risk for investors who can stomach a roller-coaster ride. At first look, Biogen seems more like a plodding drugmaker than a pending highflier: The neurology specialist boasts a market cap of about $46 billion. Second-quarter sales of $3.7 billion grew by just 2% from a year earlier. The shares trade at just 8 times this year’s adjusted...

Source: Wall Street Journal August 26, 2020 13:30 UTC